World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
30054
World Ranking
14030
National Ranking
7117

Overview

Michael W. Konstan is affiliated with Case Western Reserve University in the United States and has an extensive record of contributions primarily in the field of Medicine, with a significant focus on Pulmonary and Respiratory Medicine. Their research spans several subfields including Epidemiology, General Health Professions, Public Health, Environmental and Occupational Health, and Cardiology and Cardiovascular Medicine.

The scientist's work concentrates on specific topics such as Cystic Fibrosis Research Advances, Neonatal Respiratory Health Research, Tracheal and airway disorders, Opioid Use Disorder Treatment, Inhalation and Respiratory Drug Delivery, Health Policy Implementation Science, and Substance Abuse Treatment and Outcomes.

Selected recent publications illustrate the focus areas and include the following papers:

  • The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices, 2020, Drug and Alcohol Dependence
  • Increasing life expectancy in cystic fibrosis: Advances and challenges, 2021, Pediatric Pulmonology
  • Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF), 2020, Journal of Cystic Fibrosis
  • Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design, 2021, Annals of the American Thoracic Society
  • Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation, 2020, UNC Libraries

Frequent collaborators in their research include:

  • Donald R. VanDevanter
  • Edith T. Zemanick
  • Nicole Mayer-Hamblett
  • Shari Bolen
  • Sharon Walsh

Publication venues where Michael W. Konstan frequently publishes their work are:

  • Journal of Cystic Fibrosis
  • UNC Libraries
  • Pediatric Pulmonology
  • The Journal of Pediatrics
  • JAMA Network Open

Best Publications

  • A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

    Bonnie W. Ramsey;Jane Davies;N. Gerard McElvaney;Elizabeth Tullis

  • Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

    Jennifer L Taylor-Cousar;Anne Munck;Edward F McKone;Cornelis K van der Ent

  • Effect of high-dose ibuprofen in patients with cystic fibrosis.

    Michael W. Konstan;Pamela J. Byard;Charles L. Hoppel;Pamela B. Davis

  • Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

    Frank J. Accurso;Steven M. Rowe;J. P. Clancy;Michael P. Boyle

  • Inflammatory cytokines in cystic fibrosis lungs.

    T L Bonfield;J R Panuska;M W Konstan;K A Hilliard

  • Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

    J. P. Clancy;Steven M. Rowe;Frank J. Accurso;Moira L. Aitken

  • Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

    Michael W. Konstan;Kathleen A. Hilliard;Tonya M. Norvell;Melvin Berger

  • Genetic Modifiers of Lung Disease in Cystic Fibrosis

    Mitchell L. Drumm;Michael W. Konstan;Mark D. Schluchter;Allison Handler

  • Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy

    André M. Cantin;Dominik Hartl;Michael W. Konstan;James F. Chmiel

  • Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

    Michael W. Konstan;Wayne J. Morgan;Steven M. Butler;David J. Pasta

  • Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis.

    T L Bonfield;M W Konstan;P Burfeind;J R Panuska

  • Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis

    Michael W. Konstan;Steven M. Butler;Mary Ellen B. Wohl;Marcia Stoddard

  • Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

    Michael W. Konstan;Patrick A. Flume;Matthias Kappler;Raphaël Chiron

  • Current understanding of the inflammatory process in cystic fibrosis: onset and etiology.

    Michael W. Konstan;Melvin Berger

  • Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

    Michael W. Konstan;Pamela B. Davis;Jeffrey S. Wagener;Kathleen A. Hilliard

  • A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

    Michael P Boyle;Scott C Bell;Michael W Konstan;Susanna A McColley

  • Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

    Ronald L. Gibson;Julia Emerson;Sharon McNamara;Jane L. Burns

  • Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

    Elliott C. Dasenbrook;William Checkley;Christian A. Merlo;Michael W. Konstan

  • A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

    Joanne M. Quan;Harm A.W.M. Tiddens;Judy P. Sy;Sheila G. McKenzie

  • Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

    M. W. Konstan;K. A. Milliard;T. M. Norvell;M. Berger

Frequent Co-Authors

Wayne J. Morgan
Wayne J. Morgan University of Arizona
Bonnie W. Ramsey
Bonnie W. Ramsey University of Washington
John P. Clancy
John P. Clancy Cystic Fibrosis Foundation
Steven M. Rowe
Steven M. Rowe University of Alabama at Birmingham
Melvin Berger
Melvin Berger CSL (Switzerland)
Pamela B. Davis
Pamela B. Davis Case Western Reserve University
Richard B. Moss
Richard B. Moss Stanford University
Margaret Rosenfeld
Margaret Rosenfeld University of Washington
J. Stuart Elborn
J. Stuart Elborn Queen's University Belfast
Claire E. Wainwright
Claire E. Wainwright University of Queensland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in pursuing a medical career but want more flexible or alternative options, there are several online degrees and career pathways available in the healthcare field. For those looking to become advanced practice nurses without holding a prior nursing degree, direct entry online msn programs offer an accelerated route to a master’s in nursing, welcoming applicants from diverse backgrounds.

Individuals concerned about admissions requirements may consider easy nursing programs to get into or schools that waive traditional entrance exams such as the TEAS or HESI. If standardized tests are a barrier, explore a nursing school without teas test for a smoother application process.

For those interested in the administrative side of healthcare, medical billing and coding online schools that accept financial aid can provide career-ready training with financial assistance options. These online programs open doors to in-demand jobs, offering flexibility for working professionals or career changers.

Best Scientists Citing Michael W. Konstan

Trending Scientists